--News Direct--
Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with atezolizumab (Tecentriq®) in patients with non-small cell lung cancer. She says Tecentriq® has previously shown clinically meaningful benefit in various types of lung cancer, with six currently approved indications in the US.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/imugene-doses-first-patient-in-pd1-vaxx-combination-trial-730336593
